MIRUM PHARMACEUTICALS INC
NASDAQ: MIRM (Mirum Pharmaceuticals, Inc.)
Last update: 13 hours ago100.65
6.54 (6.94%)
| Previous Close | 94.12 |
| Open | 95.41 |
| Volume | 819,355 |
| Avg. Volume (3M) | 960,191 |
| Market Cap | 6,137,760,768 |
| Price / Earnings (Forward) | 39.68 |
| Price / Sales | 9.80 |
| Price / Book | 26.65 |
| 52 Weeks Range | |
| Earnings Date | 4 Nov 2026 |
| Profit Margin | -20.39% |
| Operating Margin (TTM) | -13.61% |
| Diluted EPS (TTM) | -1.61 |
| Quarterly Revenue Growth (YOY) | 61.20% |
| Total Debt/Equity (MRQ) | 135.97% |
| Current Ratio (MRQ) | 3.22 |
| Operating Cash Flow (TTM) | -6.85 M |
| Levered Free Cash Flow (TTM) | -23.97 M |
| Return on Assets (TTM) | -7.11% |
| Return on Equity (TTM) | -33.06% |
Market Trend
| Short Term | Medium Term | ||
| Industry | Biotechnology (US) | Mixed | Bullish |
| Biotechnology (Global) | Mixed | Bullish | |
| Stock | Mirum Pharmaceuticals, Inc. | Mixed | Bullish |
AIStockmoo Score
| Analyst Consensus | NA |
| Insider Activity | -1.5 |
| Price Volatility | 2.0 |
| Technical Moving Averages | -1.0 |
| Technical Oscillators | -0.5 |
| Average | -0.25 |
|
Mirum Pharmaceuticals Inc. is a biopharmaceutical company focused on developing and commercializing therapies for rare and orphan diseases. Its main product, Livmarli (maralixibat), is an orally administered IBAT inhibitor approved to treat cholestatic pruritus in patients with Alagille syndrome. The company is also developing treatments such as maralixibat for PFIC and ALGS, and volixibat for adult cholestatic liver diseases. Mirum currently has three approved medicines: Livmarli, Cholbam, and Ctexli. |
|
| Sector | Healthcare |
| Industry | Biotechnology |
| Investment Style | Small Growth |
| % Held by Insiders | 1.90% |
| % Held by Institutions | 114.19% |
Ownership
| Name | Date | Shares Held |
|---|---|---|
| Eventide Asset Management, Llc | 31 Mar 2026 | 1,408,871 |
| Novo Holdings A/S | 31 Mar 2026 | 1,325,000 |
No data within this time range.
| Name | Avg. Buy ($) | Avg. Sell ($) | Net Quantity | Net Value ($) |
|---|---|---|---|---|
| HOWE JOLANDA | - | 104.59 | -1,840 | -192,446 |
| Aggregate Net Quantity | -1,840 | |||
| Aggregate Net Value ($) | -192,446 | |||
| Aggregate Avg. Buy ($) | - | |||
| Aggregate Avg. Sell ($) | 104.59 | |||
| Name | Holder | Date | Type | Quantity | Price | Value ($) |
|---|---|---|---|---|---|---|
| HOWE JOLANDA | Officer | 03 Aug 2026 | Automatic sell (-) | 1,840 | 104.59 | 192,446 |
The support, resistance and trendline levels presented has been generated by an artificial intelligence (AI) model and should be interpreted with caution.
Portfolio
| Realized Profit | - |
| Unrealized Profit | - |
| Dividend Received 2026 | - |
| Total Profit | - |
| Avg. Return | - |
| Quantity (Buy) | - |
| Avg. Price (Buy) | - |
| Quantity (Sold) | - |
| Avg. Price (Sold) | - |